Cybin Archives

Psychedelics News

Cybin

Industry

15 Aug 2023

Cybin Granted U.S. Patent For Psilocybin Program

Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041...

By Microdose NewsDesk

Finance

15 Aug 2023

Cybin Reports Q1 Financial Results and Business Highlights

Cybin reports first quarter financial results and business highlights, including updates on key trials....

By Microdose

Breaking News, Finance

1 Aug 2023

Raising Capital: Cybin Announces Public Offering

Cybin has announced a public offering for gross proceeds of US$8,250,000....

By Microdose NewsDesk

Finance

28 Jun 2023

Cybin Reports 2023 Financial Results and Business Highlights

Cybin has reported audited financial results for fiscal year 2023 and recent business highlights....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

24 May 2023

Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial

Cybin announced the first participants have been dosed with CYB004 in its three-part Phase 1 clinical trial...

By Microdose NewsDesk

Industry

10 May 2023

Cybin Doses Last Patient in Part B of Phase 1 DMT Trial

Cybin Inc. announced the completion of dosing the last subject in Part B of its three-part CYB004-E Phase 1 trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) in healthy volunteers. With the...

By Microdose NewsDesk

Industry

6 Mar 2023

The Importance of Cybin’s Next-Generation Psilocybin

Cybin presented data from its ongoing next-generation psilocybin clinical trial during the company’s R&D day....

By James Hallifax

Finance

14 Feb 2023

Cybin Reports Q3 Financial Results and Business Highlights

Cybin has released its Q3 financial results and business highlights....

By Microdose NewsDesk

Industry

18 Jan 2023

Cybin Announces Promising Results From Study Measuring Psychedelic Effects on the Brain

Cybin Announces Promising Results from Kernel Flow® Study Measuring Psychedelic Effects on the Brain...

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result